论文部分内容阅读
萘丁美酮（ＮＡＢ）是一种新型非甾体抗炎药。为研究该药与阳性对照药萘普生（ＮＡＰ）对类风湿关节炎（ＲＡ）的疗效与安全性，我们对ＮＡＢ和ＮＡＰ治疗ＲＡ进行了随机、双盲、多中心和平行性的Ⅱ期临床试验。结果表明：ＮＡＢ１０００ｍｇ睡前顿服，连续４ｗｋ治疗１８８例ＲＡ的总有效率为６５．９６％，ＮＡＰ２５０ｍｇＢｉｄ连续４ｗｋ治疗１４６例ＲＡ的总有效率为６０．２７％。ＮＡＢ的不良反应发生率为１６．４１％，ＮＡＰ的不良反应发生率为３６．００％。提示ＮＡＢ治疗ＲＡ的疗效与ＮＡＰ相近，但不良反应发生率明显低于ＮＡＰ。
Nabumetone (NAB) is a novel non-steroidal anti-inflammatory drug. To investigate the efficacy and safety of the drug and the positive control naproxen (NAP) on rheumatoid arthritis (RA), we conducted a randomized, double-blind, multicenter and parallel phase II trial of NAB and NAP for RA Clinical Trials. The results showed that the total effective rate of NAB1000mg pre-sleep Dayton clothing, continuous 4wk treatment of 188 cases of RA was 65.96%, NAP250mgBid continuous 4wk treatment of 146 cases of RA total effective rate was 60.27%. The incidence of adverse reactions in NAB was 16.41%, and the incidence of adverse reactions in NAP was 36.00%. These results suggest that NAB is similar to NAP in the treatment of RA, but the incidence of adverse reactions is significantly lower than that of NAP.